Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor
Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia;...
Gespeichert in:
| Veröffentlicht in: | Anales del sistema sanitario de Navarra 2020-04, Vol.43 (1), p.103-106 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106 |
|---|---|
| container_issue | 1 |
| container_start_page | 103 |
| container_title | Anales del sistema sanitario de Navarra |
| container_volume | 43 |
| creator | De Carlos Artajo, J Castro Unanua, N Muruzábal Huarte, E Vera García, R Irigaray Echarri, A Zubiría Gortázar, J Anda Apiñániz, E |
| description | Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events. We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively. |
| doi_str_mv | 10.23938/ASSN.0859 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_23938_ASSN_0859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32242549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c220t-aee09fa9042a2680aec34337a7bb472e340abfba63af7d1aa6d662ae191e4d253</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRb0A0fLY8AFo1kgpju0mzbKqeEkVLArraGJPWqPmIduhykfwzyQUWM3mnDvSYew65jMhM7m4W242LzO-mGcnbBrHMo2SRKQTdu79B-dCyYyfsYkUQom5yqbsa21ba2DfHMjZegvBEYaK6gBNCZ4-yRHs-pZccHa77_VAGaoswsGGHaDuAkGLtR41G6wHjZ0nA0UPo9zsbdV5sDXggAU7Dh9NqKlzDdWm0cNjgtBVjbtkpyXuPV393gv2_nD_tnqK1q-Pz6vlOtJC8BAhEc9KzLgSKJIFR9JSSZliWhQqFSQVx6IsMJFYpiZGTMxQASnOYlJGzOUFuz3uatd476jMW2crdH0e8_ynYz52zMeOA3xzhNuuqMj8o38R5Td4tXTL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>De Carlos Artajo, J ; Castro Unanua, N ; Muruzábal Huarte, E ; Vera García, R ; Irigaray Echarri, A ; Zubiría Gortázar, J ; Anda Apiñániz, E</creator><creatorcontrib>De Carlos Artajo, J ; Castro Unanua, N ; Muruzábal Huarte, E ; Vera García, R ; Irigaray Echarri, A ; Zubiría Gortázar, J ; Anda Apiñániz, E</creatorcontrib><description>Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events. We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively.</description><identifier>ISSN: 1137-6627</identifier><identifier>DOI: 10.23938/ASSN.0859</identifier><identifier>PMID: 32242549</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>Antineoplastic Agents - adverse effects ; Everolimus - adverse effects ; Female ; Humans ; Hypertriglyceridemia - chemically induced ; Hypertriglyceridemia - complications ; Hypertriglyceridemia - drug therapy ; Hypolipidemic Agents - therapeutic use ; Ileal Neoplasms - drug therapy ; Middle Aged ; Neuroendocrine Tumors - drug therapy ; Pancreatitis - etiology</subject><ispartof>Anales del sistema sanitario de Navarra, 2020-04, Vol.43 (1), p.103-106</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c220t-aee09fa9042a2680aec34337a7bb472e340abfba63af7d1aa6d662ae191e4d253</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32242549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Carlos Artajo, J</creatorcontrib><creatorcontrib>Castro Unanua, N</creatorcontrib><creatorcontrib>Muruzábal Huarte, E</creatorcontrib><creatorcontrib>Vera García, R</creatorcontrib><creatorcontrib>Irigaray Echarri, A</creatorcontrib><creatorcontrib>Zubiría Gortázar, J</creatorcontrib><creatorcontrib>Anda Apiñániz, E</creatorcontrib><title>Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor</title><title>Anales del sistema sanitario de Navarra</title><addtitle>An Sist Sanit Navar</addtitle><description>Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events. We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively.</description><subject>Antineoplastic Agents - adverse effects</subject><subject>Everolimus - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertriglyceridemia - chemically induced</subject><subject>Hypertriglyceridemia - complications</subject><subject>Hypertriglyceridemia - drug therapy</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Ileal Neoplasms - drug therapy</subject><subject>Middle Aged</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Pancreatitis - etiology</subject><issn>1137-6627</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRb0A0fLY8AFo1kgpju0mzbKqeEkVLArraGJPWqPmIduhykfwzyQUWM3mnDvSYew65jMhM7m4W242LzO-mGcnbBrHMo2SRKQTdu79B-dCyYyfsYkUQom5yqbsa21ba2DfHMjZegvBEYaK6gBNCZ4-yRHs-pZccHa77_VAGaoswsGGHaDuAkGLtR41G6wHjZ0nA0UPo9zsbdV5sDXggAU7Dh9NqKlzDdWm0cNjgtBVjbtkpyXuPV393gv2_nD_tnqK1q-Pz6vlOtJC8BAhEc9KzLgSKJIFR9JSSZliWhQqFSQVx6IsMJFYpiZGTMxQASnOYlJGzOUFuz3uatd476jMW2crdH0e8_ynYz52zMeOA3xzhNuuqMj8o38R5Td4tXTL</recordid><startdate>20200420</startdate><enddate>20200420</enddate><creator>De Carlos Artajo, J</creator><creator>Castro Unanua, N</creator><creator>Muruzábal Huarte, E</creator><creator>Vera García, R</creator><creator>Irigaray Echarri, A</creator><creator>Zubiría Gortázar, J</creator><creator>Anda Apiñániz, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20200420</creationdate><title>Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor</title><author>De Carlos Artajo, J ; Castro Unanua, N ; Muruzábal Huarte, E ; Vera García, R ; Irigaray Echarri, A ; Zubiría Gortázar, J ; Anda Apiñániz, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c220t-aee09fa9042a2680aec34337a7bb472e340abfba63af7d1aa6d662ae191e4d253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2020</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Everolimus - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertriglyceridemia - chemically induced</topic><topic>Hypertriglyceridemia - complications</topic><topic>Hypertriglyceridemia - drug therapy</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Ileal Neoplasms - drug therapy</topic><topic>Middle Aged</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Pancreatitis - etiology</topic><toplevel>online_resources</toplevel><creatorcontrib>De Carlos Artajo, J</creatorcontrib><creatorcontrib>Castro Unanua, N</creatorcontrib><creatorcontrib>Muruzábal Huarte, E</creatorcontrib><creatorcontrib>Vera García, R</creatorcontrib><creatorcontrib>Irigaray Echarri, A</creatorcontrib><creatorcontrib>Zubiría Gortázar, J</creatorcontrib><creatorcontrib>Anda Apiñániz, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Anales del sistema sanitario de Navarra</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Carlos Artajo, J</au><au>Castro Unanua, N</au><au>Muruzábal Huarte, E</au><au>Vera García, R</au><au>Irigaray Echarri, A</au><au>Zubiría Gortázar, J</au><au>Anda Apiñániz, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor</atitle><jtitle>Anales del sistema sanitario de Navarra</jtitle><addtitle>An Sist Sanit Navar</addtitle><date>2020-04-20</date><risdate>2020</risdate><volume>43</volume><issue>1</issue><spage>103</spage><epage>106</epage><pages>103-106</pages><issn>1137-6627</issn><abstract>Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events. We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively.</abstract><cop>Spain</cop><pmid>32242549</pmid><doi>10.23938/ASSN.0859</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1137-6627 |
| ispartof | Anales del sistema sanitario de Navarra, 2020-04, Vol.43 (1), p.103-106 |
| issn | 1137-6627 |
| language | eng ; spa |
| recordid | cdi_crossref_primary_10_23938_ASSN_0859 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - adverse effects Everolimus - adverse effects Female Humans Hypertriglyceridemia - chemically induced Hypertriglyceridemia - complications Hypertriglyceridemia - drug therapy Hypolipidemic Agents - therapeutic use Ileal Neoplasms - drug therapy Middle Aged Neuroendocrine Tumors - drug therapy Pancreatitis - etiology |
| title | Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T12%3A08%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20lowering%20treatment%20of%20severe%20hypertriglyceridemia%20with%20acute%20pancreatitis%20caused%20by%20everolimus%20in%20a%20patient%20with%20a%20neuroendocrine%20tumor&rft.jtitle=Anales%20del%20sistema%20sanitario%20de%20Navarra&rft.au=De%20Carlos%20Artajo,%20J&rft.date=2020-04-20&rft.volume=43&rft.issue=1&rft.spage=103&rft.epage=106&rft.pages=103-106&rft.issn=1137-6627&rft_id=info:doi/10.23938/ASSN.0859&rft_dat=%3Cpubmed_cross%3E32242549%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32242549&rfr_iscdi=true |